The non-peptidic [delta]-opioid receptor agonist Tan-67 mediates neuroprotection post-ischemically and is associated with altered amyloid precursor protein expression, maturation and processing in mice

• Published in: Journal of neurochemistry Vol. 144; no. 3; p. 336
• Main Authors: Min, Jia-Wei, Liu, Yanying, Wang, David, Qiao, Fangfang, Wang, Hongmin
• Format: Journal Article
• Language: English
• Published: New York Blackwell Publishing Ltd 01.02.2018
• Subjects: Alzheimer's disease; Amyloid precursor protein; Brain; Cerebral blood flow; Chemical compounds; Ischemia; Maturation; Mice; Naltrindole; Narcotics; Neuroprotection; Occlusion; Opioid receptors (type delta); Pharmacology; Reperfusion; Rodents; Secretase; Stroke; β-Site APP-cleaving enzyme 1; β-Site APP-cleaving enzymes
• ISSN: 0022-3042; 1471-4159
• DOI: 10.1111/jnc.14265

Tan-67 is a selective non-peptidic [delta]-opioid receptor (DOR) agonist that confers neuroprotection against cerebral ischemia/reperfusion (I/R)-caused neuronal injury in pre-treated animals. In this study, we examined whether post-ischemic administration of Tan-67 in stroke mice is also neuroprotective and whether the treatment affects expression, maturation and processing of the amyloid precursor protein (APP). A focal cerebral I/R model in mice was induced by middle cerebral artery occlusion for 1 h and Tan-67 (1.5, 3 or 4.5 mg/kg) was administered via the tail vein at 1 h after reperfusion. Alternatively, naltrindole, a selective DOR antagonist (5 mg/kg), was administered 1 h before Tan-67 treatment. Our results showed that post-ischemic administration of Tan-67 (3 mg/kg or 4.5 mg/kg) was neuroprotective as shown by decreased infarct volume and neuronal loss following I/R. Importantly, Tan-67 improved animal survival and neurobehavioral outcomes. Conversely, naltrindole abolished Tan-67 neuroprotection in infarct volume. Tan-67 treatment also increased APP expression, maturation and processing in the ipsilateral penumbral area at 6 h but decreased APP expression and maturation in the same brain area at 24 h after I/R. Tan-67-induced increase in APP expression was also seen in the ischemic cortex at 24 h following I/R. Moreover, Tan-67 attenuated BACE-1 expression, [beta]-secretase activity and the BACE cleavage of APP in the ischemic cortex at 24 h after I/R, which was abolished by naltrindole. Our data suggest that Tan-67 is a promising DOR-dependent therapeutic agent for treating I/R-caused disorder and that Tan-67-mediated neuroprotection may be mediated via modulating APP expression, maturation and processing, despite an uncertain causative relationship between the altered APP and the outcomes observed.